Portal de Periódicos da CAPES

COVID-19 Vaccine: Promoting Vaccine Acceptance

2020; American College of Physicians; Volume: 174; Issue: 2 Linguagem: Inglês

10.7326/m20-8008

1539-3704

Christine Lainé, Deborah Cotton, Darilyn V. Moyer,

COVID-19 Pandemic Impacts

Special Articles21 December 2020COVID-19 Vaccine: Promoting Vaccine AcceptanceFREEChristine Laine, MD, MPH, Deborah Cotton, MD, MPH, and Darilyn V. Moyer, MDChristine Laine, MD, MPHEditor in Chief Annals of Internal Medicine Search for more papers by this author, Deborah Cotton, MD, MPHDeputy Editor Annals of Internal Medicine Search for more papers by this author, and Darilyn V. Moyer, MDExecutive Vice President and Chief Executive OfficerAmerican College of PhysiciansSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-8008 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail While many questions remain about COVID-19 vaccine, there has been great progress since mid-October 2020, when Annals of Internal Medicine and the American College of Physicians (ACP) hosted our first forum about COVID-19 vaccine (1). As we hosted our second forum on 16 December 2020, Americans and others around the globe were beginning to be vaccinated to protect them from COVID-19. Now comes the hard work of making sure sufficient numbers of people are vaccinated to end this pandemic. The vaccine does no good if it remains in freezers and vials—we need to get the vaccine into people.Internists and other clinicians must be prepared to participate in this effort. To help prepare them, Annals and ACP gathered 4 experts for a discussion of strategies to promote acceptance of vaccine—Dr. Ada Adimora from the University of North Carolina, Dr. Helene D. Gayle from the Chicago Community Trust, Dr. Peter J. Hotez from Baylor University, and Dr. Heidi J. Larson from the London School of Tropical Medicine. Dr. Ryan D. Mire, ACP Regent, and Dr. William Schaffner from Vanderbilt University moderated the discussion. Readers can view the program in the video that accompanies this article. Attendees submitted hundreds of questions ahead of time. While it was infeasible to answer all of these questions during this program, the panelists addressed many issues that appear to be on clinicians' minds.The panelists warned against dichotomizing people into those who are pro-vaccine and those who are anti-vaccine. Most people are somewhere in the middle. For sufficient numbers of people, particularly those in this middle group, to actually receive COVID-19 vaccine, immunization must be available, convenient, and affordable. Among the roughly half of Americans who are unwilling or hesitant to be vaccinated (2), we will need to not only meet these conditions but also work hard to increase their trust in the vaccine, trust in those recommending vaccine, and understanding of the true benefits and risks of COVID-19 vaccination. Unfortunately, the enormous amount of misinformation circulating on social media and other venues about vaccines in general and about COVID-19 vaccine in particular in addition to the politicization of the pandemic make this task a monumental public health challenge (3). To address this challenge, the panelists provided excellent suggestions, including the advice that follows.First, we need to battle misinformation with aggressive dissemination of accurate information about the realities of COVID-19 and the risks and benefits of vaccination. This needs to be done both in conversations with individuals and in well-crafted media campaigns delivered by trusted messengers who reflect people of color and other populations who tend to be vaccine hesitant.Second, we must acknowledge rather than dismiss people's concerns about COVID-19 vaccine. For example, we need to recognize that we currently do lack data on long-term safety and that the first vaccines to become available are based on a novel mRNA technology. To allay these concerns, it may help to reiterate what we do know about the adverse consequences of COVID-19. People need to understand what the vaccine is protecting them from so that they are able to balance the risks and benefit of vaccination. People also need to know that, although the first vaccines out of the gate are the first mRNA vaccines, this technology has been under study for nearly 2 decades. This may provide assurance that the science has not been rushed, as some vocal vaccine opponents suggest. These many years of research are what make scientists confident that mRNA vaccines will not damage recipients' genes.Third, we need to manage the public's expectations. Some people will wonder why they should be vaccinated if vaccination will not enable them to immediately discard their masks and return to life as it was in 2019. We need to emphasize that the initial goal of vaccination is to keep people well and out of hospitals and to reduce mortality. A secondary goal is to prevent transmission to a sufficient percentage of the population so that the pandemic ends. When we achieve this secondary goal, we can begin to shed our masks and gather with others.Fourth, when people are skeptical of the vaccine's effectiveness and safety, we need to let them know that the trials leading to emergency use authorization included participants with a range of ages, racial and ethnic backgrounds, and comorbidity. Further, public health messengers need to be trusted by, and to reflect, the populations they seek to reach.In summary, clinicians and public health professionals need to anticipate, validate, and be prepared to address people's questions and concerns. We must amplify sound information to combat rampant misinformation. Finally, we must demonstrate our own confidence that the benefits of vaccination outweigh the risks by being vaccinated ourselves as soon as the opportunity becomes available. Each person who accepts COVID-19 vaccine becomes an advocate for vaccination in the most unambiguous way possible.References1. Laine C, Cotton D, Moyer DV. COVID-19 vaccine: what physicians need to know. Ann Intern Med. 2020;173:830. doi:10.7326/M20-6841 LinkGoogle Scholar2. Fisher KA, Bloomstone SJ, Walder J, et al. Attitudes toward a potential SARS-CoV-2 vaccine: a survey of U.S. adults. Ann Intern Med. 2020;173:964-73. doi:10.7326/M20-3569 LinkGoogle Scholar3. Hotez PJ. Antiscience extremism in America: escalating and globalizing [Editorial]. Microbes Infect. 2020;22:505-7. [PMID: 32961275] doi:10.1016/j.micinf.2020.09.005 CrossrefMedlineGoogle Scholar Comments 0 Comments Sign In to Submit A Comment John RobbinsUC Davis21 December 2020 Why bother now? With many people wishing to take the vaccine now, why spend time and money trying to convince skeptics to take it. After many months, when 50 to 70% of the population have been vaccinated, with minimal side effects it will but much easier, and cheaper, to convince the skeptics. Dr. Thomas M. WnorowskiNutricom LLC, a research foundation21 December 2020 Drug Approval Withdrawn from the market in 2018 were more than two dozen "approved" drugs, some with a twenty-year longevity. How, then, can a one-year-old drug be trusted to be safe? All explanations are welcome. Jairo VergaraMedico23 December 2020 Pregunta People who have had covid-19, could they get the vaccine? Gaurav ChhayaSanjeevani Superspeciality hospital and research centre2 February 2021 Safer vaccination drive It is after 1st month of drive in various areas of world ... and many people inoculated vaccines .. found to be safe vaccination against COVID-19. Also acceptance is increasing all over. Question about efficacy can be answered only after 4 months. Cherylyn Y PipkinDC Government, Behavioral Health Employee16 September 2021 Informative Very informative and insightful on topics they predicted would be problematic have today proven to be true. Heather SchroederSpecialty Pharmacy29 September 2021 RN Helpful information Stephanie,LylesCNMC29 June 2022 RN Helpful information Von BrownChildren's National Medical Center14 January 2023 Vaccine advocate Hearing about the mRNA vaccines/technology interested me from the beginning. I don't mind being a messenger for those who are unsure about the misinformation. Author, Article, and Disclosure InformationAuthors: Christine Laine, MD, MPH; Deborah Cotton, MD, MPH; Darilyn V. Moyer, MDAffiliations: Editor in Chief Annals of Internal Medicine Deputy Editor Annals of Internal Medicine Executive Vice President and Chief Executive OfficerAmerican College of PhysiciansDisclosures: Disclosure forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-8008.Corresponding Author: Christine Laine, MD, MPH, Editor in Chief, Annals of Internal Medicine, 190 N. Independence Mall West, Philadelphia, PA 19106; e-mail, claine@acponline.org.This article was published at Annals.org on 21 December 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCOVID-19 Vaccine: What Physicians Need to Know Christine Laine , Deborah Cotton , and Darilyn V. Moyer COVID-19 Vaccine Distribution and Allocation: What Physicians Need to Know Christine Laine , Deborah Cotton , and Darilyn V. Moyer COVID-19 Vaccine: Practical Clinical Considerations Christine Laine , Deborah Cotton , Darilyn V. Moyer COVID-19: Evaluation and Care of Patients With Persistent Symptoms Following Acute SARS-CoV-2 Infection Christine Laine and Deborah Cotton COVID-19: Clinical and Public Health Implications of SARS-CoV-2 Immunology Christine Laine , Deborah Cotton , Darilyn V. Moyer COVID-19: Challenging Clinical Questions Christine Laine , Darilyn V. Moyer , Deborah Cotton Outpatient Evaluation and Management of COVID-19 Christine Laine , Deborah Cotton , Darilyn V. Moyer Care of Patients With New, Continuing, or Recurring Symptoms After Acute SARS-CoV-2 Infection Christine Laine and Deborah Cotton Current Clinical Challenges in the Prevention and Management of COVID-19 Christine Laine and Deborah Cotton COVID-19 Is No Longer a Public Health Emergency: Implications for Patients and Clinicians Christine Laine and Darilyn V. Moyer Metrics Cited byHesitancy or Resistance? Differential Changes in COVID-19 Vaccination Intention Between Black and White AmericansWillingness to accept COVID-19 vaccine among the elderly and the chronic disease population in ChinaCOVID-19 vaccine uptake and hesitancy among HIV-infected men who have sex with men in mainland China: a cross-sectional surveyUtilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measuresWillingness to Pay for COVID-19 Vaccines in JapanExploring Community Perceptions of COVID-19 and Vaccine Hesitancy in Selected Cities of Ethiopia: A Qualitative StudyCOVID-19 Vaccination in a Military Population: Evaluation of a Quality Improvement Initiative to Increase Vaccine Confidence and Reduce HesitancyScale Development for COVID-19 Vaccine Hesitancy by Integration of Socio-Demographic and Psychological FactorsCOVID-19 vaccine hesitancy in a developing country: prevalence, explanatory factors and implications for the futureEffectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance dataEvidence-based policies in public health to address COVID-19 vaccine hesitancyHow information processing and risk/benefit perception affect COVID-19 vaccination intention of users in online health communitiesLow COVID‐19 vaccine coverage and guardian acceptance among pediatric transplant recipientsSafety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in ChinaAnalysis of research hotspots in COVID-19 genomics based on citespace software: Bibliometric analysisEffect of Jacobsen's Relaxation Technique on the Anxiety and Job Stress of Nurses Caring COVID-19 PatientsA study on the willingness and influencing factors of novel coronavirus vaccination among medical personnel in North ChinaCOVID-19 Vaccination Concerns and Reasons for Acceptance Among US Health Care PersonnelPromoting coronavirus disease 2019 (COVID-19) vaccination among healthcare personnel: A multifaceted intervention at a tertiary-care center in JapanNon-pharmacological interventions of travel restrictions and cancelation of public events had a major reductive mortality affect during pre-vaccination coronavirus disease 2019 periodAddressing vaccine hesitancy and resistance for COVID-19 vaccinesKüresel COVID-19 aşı politikalarının kamu değeri haritalama yaklaşımı ile analiziVaccine Hesitancy of Health-Care Workers: Another Challenge in the Fight Against COVID-19 in IstanbulAttitude and Level of COVID-19 Vaccination among Women in Reproductive Age during the Fourth Pandemic Wave: A Cross-Sectional Study in PolandOpinion Polls and Antibody Response Dynamics of Vaccination with COVID-19 Booster VaccinesBarriers and Facilitators to Receiving the COVID-19 Vaccination and Development of Theoretically-Informed Implementation Strategies for the Public: Qualitative Study in Hong KongOutpatient Evaluation and Management of COVID-19Christine Laine, MD, MPH, Deborah Cotton, MD, MPH, Darilyn V. Moyer, MDPublic attitudes and influencing factors toward COVID-19 vaccination for adolescents/children: a scoping reviewCOVID-19: Challenging Clinical QuestionsChristine Laine, MD, MPH, Darilyn V. Moyer, MD, Deborah Cotton, MD, MPHCOVID-19 Vaccine Hesitancy and How to Address ItFrom COVID-19 Vaccination Intention to Actual Vaccine Uptake: A Longitudinal Study Among Chinese Adults After Six Months of a National Vaccination CampaignInfluence of COVID-19 vaccination on the dynamics of new infected cases in the worldAn Uptake of COVID-19 Vaccine: Hesitancy and the Strategies to OvercomeCOVID-19: Clinical and Public Health Implications of SARS-CoV-2 ImmunologyChristine Laine, MD, MPH, Deborah Cotton, MD, MPH, Darilyn V. Moyer, MDThe Impact of Age Difference on the Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-AnalysisPredictors of intention to get COVID‐19 vaccine: A cross‐sectional studyBody Appreciation as a Factor Associated with College Students’ Willingness to Receive Future COVID-19 VaccinesSociodemographic predictors of COVID-19 vaccine acceptance: a nationwide US-based survey studyPeoples’ understanding, acceptance, and perceived challenges of vaccination against COVID-19: A cross-sectional study in BangladeshCOVID-19: Evaluation and Care of Patients With Persistent Symptoms Following Acute SARS-CoV-2 InfectionChristine Laine, MD, MPH and Deborah Cotton, MD, MPHMandatory vaccination support and intentions to get vaccinated for COVID ‐19: Results from a nationally representative general population survey in October 2020 in GreeceCOVID-19 Mortality Rate and Its Incidence in Latin America: Dependence on Demographic and Economic VariablesDisparities in H1N1 Vaccination Rates: a Systematic Review and Evidence Synthesis to Inform COVID-19 Vaccination EffortsCOVID-19 Vaccine: Practical Clinical ConsiderationsChristine Laine, MD, MPH, Deborah Cotton, MD, MPH, Darilyn V. Moyer, MDCOVID-19 vaccination and cultural tightnessWho Goes First? Government Leaders and Prioritization of SARS-CoV-2 VaccinesStructural Mapping of Mutations in Spike, RdRp and Orf3a Genes of SARS-CoV-2 in Influenza Like Illness (ILI) Patients February 2021Volume 174, Issue 2 Page: 252-253 Keywords COVID-19 Disclosure Mortality Motivation Population statistics Prevention, policy, and public health Safety Scientists Vaccines ePublished: 21 December 2020 Issue Published: February 2021 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...